{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:10:04Z","timestamp":1766362204425,"version":"3.38.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["ZR2020MH146","ZR2020MH146","ZR2020MH146","ZR2020MH146","ZR2020MH146","ZR2020MH146","ZR2020MH146","ZR2020MH146","ZR2020MH146","ZR2020MH146","ZR2020MH146"],"award-info":[{"award-number":["ZR2020MH146","ZR2020MH146","ZR2020MH146","ZR2020MH146","ZR2020MH146","ZR2020MH146","ZR2020MH146","ZR2020MH146","ZR2020MH146","ZR2020MH146","ZR2020MH146"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-92522-7","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T08:20:02Z","timestamp":1740990002000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["YKL-40 inhibits melanoma progression and metastasis by inducing immune cell infiltration in a mouse model"],"prefix":"10.1038","volume":"15","author":[{"given":"Hailong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengqi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sipeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meihua","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yubing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"issue":"11","key":"92522_CR1","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","volume":"20","author":"LE Davis","year":"2019","unstructured":"Davis, L. E., Shalin, S. C. & Tackett, A. J. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 20(11), 1366\u20131379 (2019).","journal-title":"Cancer Biol Ther."},{"issue":"4","key":"92522_CR2","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1152\/physrev.00044.2003","volume":"84","author":"A Slominski","year":"2004","unstructured":"Slominski, A., Tobin, D. J., Shibahara, S. & Wortsman, J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol. Rev. 84(4), 1155\u20131228 (2004).","journal-title":"Physiol. Rev."},{"issue":"1","key":"92522_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jid.2020.03.943","volume":"141","author":"RW Jenkins","year":"2021","unstructured":"Jenkins, R. W. & Fisher, D. E. Treatment of advanced melanoma in 2020 and beyond. J. Invest. Dermatol. 141(1), 23\u201331 (2021).","journal-title":"J. Invest. Dermatol."},{"issue":"10304","key":"92522_CR4","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino, M. S., Larkin, J. & Long, G. V. Immune checkpoint inhibitors in melanoma. Lancet 398(10304), 1002\u20131014 (2021).","journal-title":"Lancet"},{"issue":"6","key":"92522_CR5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41591-021-01331-8","volume":"27","author":"D Liu","year":"2021","unstructured":"Liu, D. et al. Evolution of delayed resistance to immunotherapy in a melanoma responder. Nat. Med. 27(6), 985\u2013992 (2021).","journal-title":"Nat. Med."},{"key":"92522_CR6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.semcancer.2019.08.002","volume":"59","author":"M Marzagalli","year":"2019","unstructured":"Marzagalli, M., Ebelt, N. D. & Manuel, E. R. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin. Cancer Biol. 59, 236\u2013250 (2019).","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"92522_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41571-023-00848-w","volume":"21","author":"S Klobuch","year":"2024","unstructured":"Klobuch, S., Seijkens, T. T. P., Schumacher, T. N. & Haanen, J. B. A. G. Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma. Nat. Rev. Clin. Oncol. 21(3), 173\u2013184 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7637","key":"92522_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541(7637), 321\u2013330 (2017).","journal-title":"Nature"},{"issue":"6382","key":"92522_CR9","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359(6382), 1350\u20131355 (2018).","journal-title":"Science"},{"issue":"12","key":"92522_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman, W. H., Zitvogel, L., Sautes-Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14(12), 717\u2013734 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"92522_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.coi.2010.01.009","volume":"22","author":"A Mantovani","year":"2010","unstructured":"Mantovani, A. & Sica, A. Macrophages, innate immunity and cancer: Balance, tolerance, and diversity. Curr. Opin. Immunol. 22(2), 231\u2013237 (2010).","journal-title":"Curr. Opin. Immunol."},{"issue":"5","key":"92522_CR12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete, A. et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell. Mol. Immunol. 20(5), 432\u2013447 (2023).","journal-title":"Cell. Mol. Immunol."},{"issue":"2","key":"92522_CR13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf, N. K., Kissiov, D. U. & Raulet, D. H. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat. Rev. Immunol. 23(2), 90\u2013105 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"92522_CR14","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.3389\/fimmu.2018.02480","volume":"9","author":"N Jacquelot","year":"2018","unstructured":"Jacquelot, N., Duong, C. P. M., Belz, G. T. & Zitvogel, L. Targeting chemokines and chemokine receptors in melanoma and other cancers. Front. Immunol. 9, 2480 (2018).","journal-title":"Front. Immunol."},{"issue":"5","key":"92522_CR15","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/cncr.21678","volume":"106","author":"H Schmidt","year":"2006","unstructured":"Schmidt, H. et al. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106(5), 1130\u20131139 (2006).","journal-title":"Cancer"},{"issue":"2","key":"92522_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.lungcan.2004.11.011","volume":"48","author":"N Junker","year":"2005","unstructured":"Junker, N., Johansen, J. S., Andersen, C. B. & Kristjansen, P. E. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 48(2), 223\u2013231 (2005).","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"key":"92522_CR17","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1186\/s12885-015-1592-3","volume":"15","author":"M Jefri","year":"2015","unstructured":"Jefri, M., Huang, Y. N., Huang, W. C., Tai, C. S. & Chen, W. L. YKL-40 regulated epithelial-mesenchymal transition and migration\/invasion enhancement in non-small cell lung cancer. BMC Cancer 15, 590 (2015).","journal-title":"BMC Cancer"},{"issue":"17","key":"92522_CR18","doi-asserted-by":"publisher","first-page":"15332","DOI":"10.1074\/jbc.M110.212514","volume":"286","author":"RA Francescone","year":"2011","unstructured":"Francescone, R. A. et al. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J. Biol. Chem. 286(17), 15332\u201315343 (2011).","journal-title":"J. Biol. Chem."},{"issue":"3","key":"92522_CR19","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.3390\/cancers2031453","volume":"2","author":"NA Schultz","year":"2010","unstructured":"Schultz, N. A. & Johansen, J. S. YKL-40-A protein in the field of translational medicine: A role as a biomarker in cancer patients?. Cancers (Basel) 2(3), 1453\u20131491 (2010).","journal-title":"Cancers (Basel)"},{"issue":"6","key":"92522_CR20","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1189\/jlb.3VMR0415-142R","volume":"98","author":"S Libreros","year":"2015","unstructured":"Libreros, S. & Iragavarapu-Charyulu, V. YKL-40\/CHI3L1 drives inflammation on the road of tumor progression. J. Leukoc. Biol. 98(6), 931\u2013936 (2015).","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"92522_CR21","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1080\/07853890.2021.1950920","volume":"53","author":"H Hao","year":"2021","unstructured":"Hao, H., Chen, H., Xie, L. & Liu, H. YKL-40 promotes invasion and metastasis of bladder cancer by regulating epithelial mesenchymal transition. Ann. Med. 53(1), 1170\u20131178 (2021).","journal-title":"Ann. Med."},{"issue":"8","key":"92522_CR22","first-page":"3749","volume":"9","author":"H Hao","year":"2017","unstructured":"Hao, H. et al. YKL-40 promotes the migration and invasion of prostate cancer cells by regulating epithelial mesenchymal transition. Am. J. Transl. Res. 9(8), 3749\u20133757 (2017).","journal-title":"Am. J. Transl. Res."},{"issue":"7","key":"92522_CR23","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1097\/IGC.0000000000000774","volume":"26","author":"LL Li","year":"2016","unstructured":"Li, L. L., Fan, J. T., Li, D. H. & Liu, Y. Effects of a small interfering RNA targeting YKL-40 gene on the proliferation and invasion of endometrial cancer HEC-1A cells. Int. J. Gynecol. Cancer 26(7), 1190\u20131195 (2016).","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"7","key":"92522_CR24","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1080\/15384101.2021.1901037","volume":"20","author":"CB Holst","year":"2021","unstructured":"Holst, C. B. et al. Perspective: Targeting VEGF-A and YKL-40 in glioblastoma - matter matters. Cell Cycle 20(7), 702\u2013715 (2021).","journal-title":"Cell Cycle"},{"issue":"16","key":"92522_CR25","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.7150\/thno.26467","volume":"8","author":"KC Kim","year":"2018","unstructured":"Kim, K. C. et al. Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1. Theranostics 8(16), 4409\u20134428 (2018).","journal-title":"Theranostics"},{"issue":"2","key":"92522_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/carcin\/bgt380","volume":"35","author":"R Shao","year":"2014","unstructured":"Shao, R. et al. Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma. Carcinogenesis 35(2), 373\u2013382 (2014).","journal-title":"Carcinogenesis"},{"issue":"17","key":"92522_CR27","doi-asserted-by":"publisher","first-page":"6354","DOI":"10.3390\/ijms21176354","volume":"21","author":"K Kang","year":"2020","unstructured":"Kang, K. et al. Selection and characterization of YKL-40-targeting monoclonal antibodies from human synthetic fab phage display libraries. Int. J. Mol. Sci. 21(17), 6354 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"92522_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095822","volume":"9","author":"J Salamon","year":"2014","unstructured":"Salamon, J. et al. Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice. PLoS One 9(4), e95822 (2014).","journal-title":"PLoS One"},{"issue":"5","key":"92522_CR29","first-page":"1383","volume":"18","author":"K Erturk","year":"2017","unstructured":"Erturk, K., Tas, F., Serilmez, M., Bilgin, E. & Yasasever, V. Clinical significance of serum Ykl-40 (Chitinase-3-Like-1 Protein) as a biomarker in melanoma: An analysis of 112 Turkish patients. Asian Pac. J. Cancer Prev. 18(5), 1383\u20131387 (2017).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"92522_CR30","first-page":"1286","volume":"70","author":"A Rusak","year":"2016","unstructured":"Rusak, A., Jablonska, K. & Dziegiel, P. The role of YKL-40 in a cancerous process. Postepy higieny i medycyny doswiadczalnej (Online). 70, 1286\u20131299 (2016).","journal-title":"Postepy higieny i medycyny doswiadczalnej (Online)."},{"issue":"4","key":"92522_CR31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/CMR.0000000000000237","volume":"26","author":"M Krogh","year":"2016","unstructured":"Krogh, M. et al. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma. Melanoma Res. 26(4), 367\u2013376 (2016).","journal-title":"Melanoma Res."},{"key":"92522_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejca.2019.08.025","volume":"121","author":"H Ismail","year":"2019","unstructured":"Ismail, H. et al. Measured and genetically predicted plasma YKL-40 levels and melanoma mortality. Eur. J. Cancer 121, 74\u201384 (2019).","journal-title":"Eur. J. Cancer"},{"key":"92522_CR33","first-page":"6610769","volume":"2021","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. Serum cytokine profiles of melanoma patients and their association with tumor progression and metastasis. J. Oncol. 2021, 6610769 (2021).","journal-title":"J. Oncol."},{"issue":"10","key":"92522_CR34","doi-asserted-by":"publisher","first-page":"8901","DOI":"10.3390\/ijms24108901","volume":"24","author":"V Koroknai","year":"2023","unstructured":"Koroknai, V., Sz\u00e1sz, I. & Bal\u00e1zs, M. Gene expression changes in cytokine and chemokine receptors in association with melanoma liver metastasis. Int. J. Mol. Sci. 24(10), 8901 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"92522_CR35","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1016\/j.immuni.2023.11.002","volume":"56","author":"T Taifour","year":"2023","unstructured":"Taifour, T. et al. The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer. Immunity 56(12), 2755\u20132772 (2023).","journal-title":"Immunity"},{"key":"92522_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216184","volume":"563","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. YKL-40 derived from infiltrating macrophages cooperates with GDF15 to establish an immune suppressive microenvironment in gallbladder cancer. Cancer Lett. 563, 216184 (2023).","journal-title":"Cancer Lett."},{"issue":"4","key":"92522_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41568-022-00442-9","volume":"22","author":"S Kalaora","year":"2022","unstructured":"Kalaora, S., Nagler, A., Wargo, J. A. & Samuels, Y. Mechanisms of immune activation and regulation: lessons from melanoma. Nature Reviews Cancer. 22(4), 195\u2013207 (2022).","journal-title":"Nature Reviews Cancer."},{"issue":"1","key":"92522_CR38","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1172\/JCI120391","volume":"129","author":"L Poncette","year":"2019","unstructured":"Poncette, L., Chen, X., Lorenz, F. K. & Blankenstein, T. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression. J. Clin. Invest. 129(1), 324\u2013335 (2019).","journal-title":"J. Clin. Invest."},{"issue":"21","key":"92522_CR39","doi-asserted-by":"publisher","first-page":"8368","DOI":"10.1158\/0008-5472.CAN-10-1322","volume":"70","author":"R Bos","year":"2010","unstructured":"Bos, R. & Sherman, L. A. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 70(21), 8368\u20138377 (2010).","journal-title":"Cancer Res."},{"issue":"3","key":"92522_CR40","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1084\/jem.20091918","volume":"207","author":"SA Quezada","year":"2010","unstructured":"Quezada, S. A. et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207(3), 637\u2013650 (2010).","journal-title":"J. Exp. Med."},{"issue":"3","key":"92522_CR41","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s43018-023-00521-2","volume":"4","author":"DE Speiser","year":"2023","unstructured":"Speiser, D. E., Chijioke, O., Schaeuble, K. & M\u00fcnz, C. CD4(+) T cells in cancer. Nat. Cancer 4(3), 317\u2013329 (2023).","journal-title":"Nat. Cancer"},{"issue":"2","key":"92522_CR42","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1171447","volume":"6","author":"B Seliger","year":"2017","unstructured":"Seliger, B., Kloor, M. & Ferrone, S. HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance. Oncoimmunology 6(2), e1171447 (2017).","journal-title":"Oncoimmunology"},{"issue":"8","key":"92522_CR43","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-18-3200","volume":"25","author":"ML Axelrod","year":"2019","unstructured":"Axelrod, M. L., Cook, R. S., Johnson, D. B. & Balko, J. M. Biological consequences of MHC-II expression by tumor cells in cancer. Clin. Cancer Res. 25(8), 2392\u20132402 (2019).","journal-title":"Clin. Cancer Res."},{"issue":"7910","key":"92522_CR44","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-022-04682-5","volume":"605","author":"G Oliveira","year":"2022","unstructured":"Oliveira, G. et al. Landscape of helper and regulatory antitumour CD4(+) T cells in melanoma. Nature 605(7910), 532\u2013538 (2022).","journal-title":"Nature"},{"issue":"24","key":"92522_CR45","doi-asserted-by":"publisher","first-page":"9709","DOI":"10.1073\/pnas.85.24.9709","volume":"85","author":"AM Weissman","year":"1988","unstructured":"Weissman, A. M. et al. Molecular cloning and chromosomal localization of the human T-cell receptor zeta chain: Distinction from the molecular CD3 complex. Proc. Natl. Acad. Sci. USA 85(24), 9709\u20139713 (1988).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"92522_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13170","volume":"96","author":"C Dexiu","year":"2022","unstructured":"Dexiu, C., Xianying, L., Yingchun, H. & Jiafu, L. Advances in CD247. Scand. J. Immunol. 96(1), e13170 (2022).","journal-title":"Scand. J. Immunol."},{"issue":"11","key":"92522_CR47","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1002\/j.1460-2075.1993.tb06119.x","volume":"12","author":"M Malissen","year":"1993","unstructured":"Malissen, M. et al. T cell development in mice lacking the CD3-zeta\/eta gene. Embo J. 12(11), 4347\u20134355 (1993).","journal-title":"Embo J."},{"issue":"5123","key":"92522_CR48","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1126\/science.7688481","volume":"261","author":"PE Love","year":"1993","unstructured":"Love, P. E. et al. T cell development in mice that lack the zeta chain of the T cell antigen receptor complex. Science 261(5123), 918\u2013921 (1993).","journal-title":"Science"},{"issue":"12","key":"92522_CR49","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1002\/j.1460-2075.1993.tb06176.x","volume":"12","author":"CP Liu","year":"1993","unstructured":"Liu, C. P. et al. Abnormal T cell development in CD3-zeta-\/- mutant mice and identification of a novel T cell population in the intestine. Embo J. 12(12), 4863\u20134875 (1993).","journal-title":"Embo J."},{"issue":"8","key":"92522_CR50","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00403-002-0343-x","volume":"294","author":"M Alaibac","year":"2002","unstructured":"Alaibac, M., Pigozzi, B., Saponeri, A., Belloni-Fortina, A. & Peserico, A. Absent or low expression of T-cell receptor zeta-chain in T cells infiltrating human pathological skin conditions. Arch. Dermatol. Res. 294(8), 380\u2013382 (2002).","journal-title":"Arch. Dermatol. Res."},{"key":"92522_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcp.2023.101925","volume":"72","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z. et al. CD3\u03b6 as a novel predictive biomarker of PD-1 inhibitor resistance in melanoma. Mol. Cell. Probes. 72, 101925 (2023).","journal-title":"Mol. Cell. Probes."},{"issue":"9","key":"92522_CR52","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.3390\/cells10092320","volume":"10","author":"C Teixido","year":"2021","unstructured":"Teixido, C., Castillo, P., Martinez-Vila, C., Arance, A. & Alos, L. Molecular markers and targets in melanoma. Cells 10(9), 2320 (2021).","journal-title":"Cells"},{"issue":"1","key":"92522_CR53","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.det.2022.07.007","volume":"41","author":"J Lazaroff","year":"2023","unstructured":"Lazaroff, J. & Bolotin, D. Targeted therapy and immunotherapy in melanoma. Dermatol. Clin. 41(1), 65\u201377 (2023).","journal-title":"Dermatol. Clin."},{"issue":"1","key":"92522_CR54","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","volume":"6","author":"W Guo","year":"2021","unstructured":"Guo, W., Wang, H. & Li, C. Signal pathways of melanoma and targeted therapy. Signal Transduct. Target Ther. 6(1), 424 (2021).","journal-title":"Signal Transduct. Target Ther."},{"issue":"D1","key":"92522_CR55","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: Biological systems database as a model of the real world. Nucleic Acids Res. 53(D1), D672\u2013D677 (2025).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92522-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92522-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92522-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:51:36Z","timestamp":1741348296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92522-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["92522"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-92522-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal experiments were approved by the Ethics Committee of Weifang No.2 People\u2019s Hospital (approval no. 2024LAC019; Weifang, China).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"7426"}}